Movement Disorder News and Research RSS Feed - Movement Disorder News and Research

Movement disorders are neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness, paralysis of spasticity of the muscles. They affect the speed, fluency or smoothness, quality, and ease of movement.
UC San Diego Health System's Movement Disorder Center joins NPF Center of Excellence network

UC San Diego Health System's Movement Disorder Center joins NPF Center of Excellence network

The Movement Disorder Center at UC San Diego Health System has been designated the 41st Center of Excellence in the National Parkinson Foundation's global network. This designation is the highest recognition offered by NPF to a Parkinson's specialty clinic. It represents the consensus of leaders in the field that the UC San Diego program is among the world's leading centers for Parkinson's research, outreach and care. [More]
New study finds that statins may not reduce risk for Parkinson's disease

New study finds that statins may not reduce risk for Parkinson's disease

The use of statins may not be associated with lowering risk for Parkinson's disease, according to a new study led by researchers at Penn State College of Medicine and National Institute of Environmental Health Sciences. The findings cast doubts on reports suggesting that the cholesterol-lowering medications may protect against this neurodegenerative brain disorder. [More]
Movement Disorder Center at UC San Diego designated Center of Excellence in NPF's global network

Movement Disorder Center at UC San Diego designated Center of Excellence in NPF's global network

The Movement Disorder Center at UC San Diego Health System has been designated the 41st Center of Excellence in the National Parkinson Foundation's global network. This competitive designation is the highest recognition offered by NPF to a Parkinson's specialty clinic and represents the consensus of leaders in the field that the multidisciplinary clinic at UC San Diego Health System is among the world's leading centers for Parkinson's research, outreach and care. [More]
FDA approves RYTARY for Parkinson's disease treatment

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication. [More]
Methamphetamine use may increase Parkinson's disease risk

Methamphetamine use may increase Parkinson's disease risk

In addition to incurring serious dental problems, memory loss and other physical and mental issues, methamphetamine users are three times more at risk for getting Parkinson's disease than non-illicit drug users, new research from the University of Utah and Intermountain Healthcare shows. [More]
Patients with Parkinson's disease have different microbiota in their intestines

Patients with Parkinson's disease have different microbiota in their intestines

Parkinson's disease sufferers have a different microbiota in their intestines than their healthy counterparts, according to a study conducted at the University of Helsinki and the Helsinki University Central Hospital. Researchers are now trying to determine what the connection between intestinal microbes and Parkinson's disease is. [More]
Lewy body dementia: 10 things people need to know

Lewy body dementia: 10 things people need to know

The recent news that the brain of actor/comedian Robin Williams showed signs of diffuse Lewy body disease has created more interest and coverage in this widely under-diagnosed condition than ever before. [More]
Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax Laboratories (Netherlands) B.V., a wholly owned subsidiary of Impax Laboratories, Inc. today announced that it has submitted a Marketing Authorization Application for IPX066 to the European Medicines Agency. IPX066 is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson's disease. [More]
Migraine in middle age linked to Parkinson's disease

Migraine in middle age linked to Parkinson's disease

A paper recently published in American Academy of Neurology suggests that migraine in middle age may indicate an increased risk of developing a movement disorder, such as Parkinson’s disease. The study also showed that people who experienced migraine with aura were twice as likely to develop Parkinson’s disease compared with those who did not suffer from headaches. [More]
Vercise DBS System receives CE Mark approval for treatment of essential tremor

Vercise DBS System receives CE Mark approval for treatment of essential tremor

Boston Scientific Corporation has received CE Mark for the Vercise Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement disorder known as essential tremor (ET). [More]
Low accuracy of clinical diagnosis for early Parkinson’s disease

Low accuracy of clinical diagnosis for early Parkinson’s disease

About three-quarters of patients suspected to have early Parkinson’s disease eventually prove to have other conditions, a study shows. [More]
Studies show relation between spice and different types of psychosis

Studies show relation between spice and different types of psychosis

Professors of Medicine Degree at the CEU Cardenal Herrera University and the Provincial Hospital of Castellón, in collaboration with doctors of the Addictive Behaviors Unit of Valencia, have described the first case of catatonic psychosis caused by a synthetic derivate of Cannabis: the spice. [More]
New research program to understand and treat debilitating psychiatric disorders

New research program to understand and treat debilitating psychiatric disorders

Scientists and physicians at UC San Francisco (UCSF) are leading a $26 million, multi-institutional research program in which they will employ advanced technology to characterize human brain networks and better understand and treat a range of common, debilitating psychiatric disorders, focusing first on anxiety disorders and major depression. [More]
Eye movement disorder increases as we age, study finds

Eye movement disorder increases as we age, study finds

Abnormal binocular vision, which involves the way eyes work together as a team, increases dramatically as we age, according to research from the University of Waterloo. The study also found a correlation between this condition, general health and antidepressant use. [More]
Studies demonstrate new approaches to treating and preventing Parkinson's disease

Studies demonstrate new approaches to treating and preventing Parkinson's disease

A trio of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate new approaches to understanding, treating and potentially staving off Parkinson's disease (PD). Studies show that factors such as estrogen exposure and statin use have an impact on the onset of Parkinson's disease. [More]
Study reveals factors that contribute to eye mobility disorder

Study reveals factors that contribute to eye mobility disorder

Imagine you cannot move your eyes up, and you cannot lift your upper eyelid. You walk through life with your head tilted upward so that your eyes look straight when they are rolled down in the eye socket. [More]
Impax resubmits NDA for RYTARY providing updated safety and stability information

Impax resubmits NDA for RYTARY providing updated safety and stability information

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA). [More]
Scientists work together to get a better understanding of Parkinson's disease

Scientists work together to get a better understanding of Parkinson's disease

Each day, 80 people are newly diagnosed with Parkinson's disease (PD) in the UK and one in 20 will be under the age of 40. [More]

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company’s fourth in the past eight months focused on technology for Parkinson’s disease diagnostics and treatment. [More]
Researchers identify high levels of certain protein in brains of people suffering from essential tremor

Researchers identify high levels of certain protein in brains of people suffering from essential tremor

A team of researchers from Universit- Laval and CHU de Qu-bec identified unusually high levels of a certain protein in the brains of people suffering from essential tremor (ET), a movement disorder that affects 4% of the adult population. [More]
Advertisement